Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes
Kura Oncology and its newly formed spinout Caspian Therapeutics outlined the development strategy for KO-7246, an oral menin inhibitor being positioned for diabetes, with positive preclinical data presented at the EASD annual meeting. In mouse and rat models, KO-7246 expanded insulin-producing beta cells, improved glucose control — including in combination with semaglutide — and showed durable benefit after treatment stopped, with no hypoglycemia observed. Kura launched Caspian in September 2026 with a $50 million financing led by BVF Partners with participation from Eli Lilly and others; Kura contributed the asset and retains roughly half ownership.
Key figures
- Drug Name
- KO-7246
- Deal Value Usd
- 50000000
- Phase Of Trial
- IND-enabling, Phase 1 planned
- Caspian launch
- September 2026
- Kura ownership of caspian
- approximately half
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.